General Biologicals Corporation (TPEX:4117)
Taiwan · Delayed Price · Currency is TWD 10.20
-0.25 (-2.39%)
Jul 30, 2026, 1:41 PM CST
General Biologicals Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 740 | 782 | 1,274 | 1,615 | 1,609 | 2,082 | |
Market Cap Growth | -22.00% | -38.66% | -21.11% | 0.37% | -22.70% | -35.56% |
Enterprise Value | 2,603 | 3,100 | 2,957 | 1,885 | 1,528 | 2,168 |
Last Close Price | 10.45 | 12.85 | 20.26 | 26.11 | 26.01 | 33.65 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 1.40 | 1.68 | - | - | - | 47.16 |
PS Ratio | 3.43 | 3.62 | 5.06 | 6.10 | 4.34 | 3.77 |
PB Ratio | 0.85 | 0.90 | 4.45 | 3.25 | 2.32 | 2.83 |
P/TBV Ratio | 0.90 | 0.96 | 5.53 | 3.69 | 2.56 | 3.13 |
P/FCF Ratio | - | - | - | - | - | 85.87 |
P/OCF Ratio | - | - | - | 7.16 | 7.15 | 53.42 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 12.07 | 14.37 | 11.74 | 7.12 | 4.13 | 3.93 |
EV/EBITDA Ratio | - | - | - | - | - | 33.38 |
EV/EBIT Ratio | - | - | - | - | - | 49.51 |
EV/FCF Ratio | - | - | - | - | - | 89.43 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 2.86 | 2.86 | 8.06 | 1.10 | 0.68 | 0.61 |
Debt / EBITDA Ratio | - | - | - | - | - | 5.71 |
Debt / FCF Ratio | - | - | - | - | - | 18.54 |
Net Debt / Equity Ratio | 2.13 | 2.13 | 7.18 | 0.67 | 0.17 | 0.11 |
Net Debt / EBITDA Ratio | -14.18 | -14.18 | -10.54 | -2.20 | -5.19 | 1.24 |
Net Debt / FCF Ratio | -6.06 | -6.06 | -1.19 | -1.67 | -5.03 | 3.33 |
Asset Turnover | 0.05 | 0.05 | 0.08 | 0.13 | 0.26 | 0.53 |
Inventory Turnover | 2.69 | 2.69 | 3.43 | 2.00 | 2.01 | 3.69 |
Quick Ratio | 1.78 | 1.78 | 0.80 | 0.29 | 4.21 | 5.40 |
Current Ratio | 2.00 | 2.00 | 1.15 | 0.39 | 5.62 | 6.62 |
Return on Equity (ROE) | 80.22% | 80.22% | -56.65% | -33.60% | -7.54% | 6.20% |
Return on Assets (ROA) | -2.95% | -2.95% | -4.48% | -5.20% | -1.81% | 2.61% |
Return on Invested Capital (ROIC) | -6.63% | -7.14% | -13.60% | -20.74% | -5.03% | 8.00% |
Return on Capital Employed (ROCE) | -4.40% | -4.40% | -7.00% | -11.30% | -2.80% | 3.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 62.94% | 59.60% | -17.33% | -12.31% | -3.31% | 2.12% |
FCF Yield | -41.52% | -39.31% | -136.13% | -12.28% | -1.46% | 1.17% |
Buyback Yield / Dilution | -4.62% | -4.62% | - | - | 0.14% | -13.44% |